Loading company
Pharming Group N.V.
PHAR · Nasdaq · ·
Next earnings: November 5, 2026
$10.18-4.0%Sep 29 close
- 1M
- -13.0%
- 6M
- -36.4%
- 1Y
- -29.8%
- 5Y
- +4.6%
PHAR · Nasdaq · ·
Next earnings: November 5, 2026
$10.18-4.0%Sep 29 close
Pharming Group N.V. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toMar 31, 2020 | Change |
|---|---|---|---|
| Total Revenue | $106.5M | $54.5M | +95.41% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Pharming Group N.V. filed on July 30, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Pharming Group N.V. has no earnings call transcript available.